Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Acarix doubles revenue in Q2 2026, stock falls despite growth

Acarix reported a 102% increase in revenue in the second quarter (108% currency-adjusted), driven by strong US growth and a doubling of patch sales in the US. System deliveries rose 53% to 29 units, operating expenses fell 19% quarter-on-quarter, and liquid funds were around 29 million SEK. Despite the progress, the company remained unprofitable with a net loss of 9.4 million SEK, and the stock fell 3.29% pre-market. Management highlights additional growth drivers such as CPT-1 reimbursement in the US, international approvals and ongoing investments in commercialization. » Mere på de.investing.com
Acarix reports strong US-driven revenue growth in Q2 2026, shares fall

Acarix reported Q2 2026 revenue of about SEK 2.3m, up 102% (currency-adjusted 108%), with US sales growing 212–223%. System deliveries rose 53% in the quarter to 29 units and US sales of patches doubled to 140 packs. Operating expenses fell 19% versus the prior quarter, net loss was SEK 9.4m, cash was around SEK 29m and monthly cash burn about SEK 3m. Management sees drivers in US reimbursement (target: CPT-1 in H1 2027), an ongoing US performance study with publication expected before end-2026, and international expansion, but warns of continued uneven growth and reimbursement risks. » Mere på de.investing.com
Acarix increases Q4 revenue by 26% thanks to accelerated market adoption of the CADScor system

Acarix reports Q4 2025 revenue of SEK 2,141k, up 26% year‑on‑year, driven by an 87% revenue jump in the US. CADScor system shipments rose 64% to 23 units and consumables sales increased 73%, indicating higher system utilization. Operating costs fell 23% and the net loss improved by 27%, while the monthly burn rate declined by 37%. Growing reimbursement in the US, EU‑MDR certification and a sales agreement in Saudi Arabia underpin the expansion strategy. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde ACARIX AB en omsætning på 208,27 t € og et nettoresultat på -855,63 t €

(EUR)	juni 2026	YoY
Omsætning	208,27 t	103,56 %
Bruttofortjeneste	83,92 t	12,45 %
Nettoresultat	-855,63 t	25,88 %
EBITDA	-749,87 t	30,18 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	21,44 mio. €
Antal aktier	1,12 mia.
Højeste/laveste i 52 uger	0,0309 € - 0,0177 €
Udbytte	Nej
Beta	-0,21
P/E (PE Ratio)	-6,34
PEG (PEG Ratio)	-0,11
K/I (PB Ratio)	5,97
P/S (PS Ratio)	26,25

Virksomhedsprofil

Acarix AB (publ), ein Medizintechnikunternehmen, entwickelt und vertreibt diagnostische Tests für Herz-Kreislauf-Erkrankungen in Deutschland, Schweden, dem Nahen Osten, der Schweiz, Österreich und international. Das Unternehmen bietet das CADScor System an, ein nicht-invasives und hochempfindliches Analysegerät für die Diagnose der koronaren Herzkrankheit. Acarix AB (publ) wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in Malmö, Schweden.